Autolus Therapeutics (AUTL) Prices 7.25M ADS Offering at $11/ADS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/21/2026
- US stock futures rise after previous session's selloff
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Wall Street sinks as bond yields rise, Walmart results disappoint
- Wolfe remains "broadly bullish on AI semis stocks", names Top Pick
- Supermicro probe finds no senior management link to export violations
- SpaceX shares fall as second lockup period ends
- Hertz Global amends voting agreement with CK Amarillo after lawsuit
Autolus Therapeutics (AUTL) Announces 7.25M Proposed Public Offering of ADSs
January 22, 2020 4:42 PM ESTAutolus Therapeutics plc (Nasdaq: AUTL), a clinical-stage biopharmaceutical company developing next-generation programmed T cell therapies, today announced that it has commenced an offering of up to 7,250,000 American Depositary Shares (ADSs) representing 7,250,000 ordinary shares in an underwritten public offering in the United States.... More
